Suppression of Hepatocyte Growth Factor Production Impairs the Ability of Adipose-Derived Stem Cells to Promote Ischemic Tissue Revascularization
- 27 September 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in The International Journal of Cell Cloning
- Vol. 25 (12), 3234-3243
- https://doi.org/10.1634/stemcells.2007-0388
Abstract
The use of adipose-derived stem/stromal cells (ASCs) for promoting repair of tissues is a promising potential therapy, but the mechanisms of their action are not fully understood. We and others previously demonstrated accelerated reperfusion and tissue salvage by ASCs in peripheral ischemia models and have shown that ASCs secrete physiologically relevant levels of hepatocyte growth factor (HGF) and vascular endothelial growth factor. The specific contribution of HGF to ASC potency was determined by silencing HGF expression. RNA interference was used to downregulate HGF expression. A dual-cassette lentiviral construct expressing green fluorescent protein (GFP) and either a small hairpin RNA specifically targeted to HGF mRNA (shHGF) or an inactive control sequence (shCtrl) were used to stably transduce ASCs (ASC-shHGF and ASC-shCtrl, respectively). Transduced ASC-shHGF secreted >80% less HGF, which led to a reduced ability to promote survival, proliferation, and migration of mature and progenitor endothelial cells in vitro. ASC-shHGF were also significantly impaired, compared with ASC-shCtrl, in their ability to promote reperfusion in a mouse hindlimb ischemia model. The diminished ability of ASCs with silenced HGF to promote reperfusion of ischemic tissues was reflected by reduced densities of capillaries in reperfused tissues. In addition, fewer GFP+ cells were detected at 3 weeks in ischemic limbs of mice treated with ASC-shHGF compared with those treated with ASC-shCtrl. These results indicate that production of HGF is important for the potency of ASCs. This finding directly supports the emerging concept that local factor secretion by donor cells is a key element of cell-based therapies. Disclosure of potential conflicts of interest is found at the end of this article.Keywords
This publication has 50 references indexed in Scilit:
- Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cellsJournal of Molecular and Cellular Cardiology, 2005
- Therapeutical potential of blood-derived progenitor cells in patients with peripheral arterial occlusive disease and critical limb ischaemiaEuropean Heart Journal, 2005
- Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cellsNature Medicine, 2005
- Autologous Peripheral Blood Stem Cell Transplantation for Myocardial Regeneration: A Novel Strategy for Cell Collection and Surgical InjectionThe Annals of Thoracic Surgery, 2004
- Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarctionJournal of the American College of Cardiology, 2004
- Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trialThe Lancet, 2004
- Therapeutic Angiogenesis by Autologous Bone Marrow Cell Implantation for Refractory Chronic Peripheral Arterial Disease Using Assessment of Neovascularization by 99mTc-Tetrofosmin (TF) Perfusion ScintigraphyCell Transplantation, 2004
- Secretion of Angiogenic and Antiapoptotic Factors by Human Adipose Stromal CellsCell Metabolism, 2004
- Autologous Bone-Marrow Mononuclear Cell Implantation Improves Endothelium-Dependent Vasodilation in Patients With Limb IschemiaCirculation, 2004
- Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trialThe Lancet, 2002